差别性释放两种药物的层层组装聚合物膜

基于层层组装技术制备了能够差别性释放2种药物的聚合物复合膜.通过大分子前体药物透明质酸-阿霉素(HA-DOX)与壳聚糖(HACC)的层层组装以及膜内后扩散负载甲氨喋呤二钠盐(MTX)的方法,实现了DOX和MTX 2种药物分子在聚合物膜中的负载.DOX和MTX在癌变组织的酸性环境下具有差别性的释放动力学,MTX在24 h内快速释放,而DOX长效缓释达10 d.细胞实验结果表明,差别性释放的DOX和MTX可有效地抑制癌细胞的增殖.     

靶向纳米钻石-甲氨蝶呤药物体系制备及与MCF-7细胞作用

以羧基化纳米钻石(ND-COOH)为基体, 通过共价键合方法将聚乙二醇二胺(H₂N-PEG-NH₂)、 叶酸(FA)和缩水甘油(GLY)偶联于ND-COOH表面, 赋予纳米钻石载体较好的水溶分散性和靶向性, 借助氢键和范德华力等作用力负载甲氨蝶呤(MTX), 得到靶向纳米钻石-聚乙二醇二胺-叶酸/缩水甘油/甲氨蝶呤(ND-PEG-FA/GLY/MTX NPF/G/M)纳米药物体系. 采用透射电子显微镜、 X射线能量色散谱、 粒径及电位测试证实已制备NPF/G/M. 体外释药发现NPF/G/M在肿瘤环境(pH=5.5)中的药物释放量为正常生理环境(pH=7.4)中的3倍, 表明其具有良好的药物输送特性. 此外, 利用流式细胞术和MTT毒性测试探究了MCF-7细胞摄取NPF/G/M的机制及动力学特性和细胞毒性, 结果表明NPF/G/M以依赖能量、 温度、 网格蛋白、 小窝蛋白和叶酸受体介导的机制进入细胞, 从而将药物缓慢释放于细胞内, 进而诱导细胞凋亡. 研究结果表明, NPF/G/M可作为一种良好的药物输送体系, 为其应用于乳腺癌的临床治疗提供理论参考.     

磁性凹凸棒土温敏性微凝胶的合成及其体外实验（英文）

通过乳液聚合法制备了叶酸(FA)接枝的磁性FA-Fe_3O_4/凹凸棒土-聚(N-异丙基丙烯酰胺-丙烯酰胺)(FA-Fe_3O_4/ATPP(NIPAM-AAM))复合微凝胶(凹凸棒土=ATP,N-异丙基丙烯酰胺=NIPAM,丙烯酰胺=AAM),并通过X射线衍射(XRD)、振动样品磁强计(VSM)、热重(TG)、红外分析(IR)、紫外可见分光光度仪(UV)、扫描电子显微镜(SEM)和透射电子显微镜(TEM)对其进行表征。通过动态光散射(DLS)测定的低临界溶液温度(LCST)约为38.5℃,该温度适合于细胞实验。选择盐酸阿霉素(DOX)作为模型药物。药物负载和释放试验表明,ATP可以增加药物的负载和释放量。体外细胞毒性实验表明,与游离DOX相比,负载DOX的FA-Fe_3O_4/ATP-P(NIPAM-AAM)具有更好的生物相容性,并有望建立一个药物缓释系统。体外细胞摄取实验表明,FA-Fe_3O_4/ATP-P(NIPAM-AAM)具有靶向性,可用于靶向药物释放。     

刺激响应共负载药物/基因微载体的制备

合成了聚乙烯亚胺接枝二茂铁(PEI-Fc)两亲聚合物, 采用水包油法制备包埋疏水性抗癌药阿霉素(DOX)的载药胶束, 并利用胶束表面正电荷的PEI链段有效缔合DNA, 获得尺寸合适、 表面带正电荷的阿霉素与基因共负载微载体. 在磷酸盐(PBS)缓冲溶液中, 共负载微载体能够缓慢释放出DOX. 在硝酸铈铵存在下, 二茂铁从疏水性转变为亲水性, 使载药胶束完全解离, 由于PEI-Fc与DNA之间的静电作用, 使基因超分子组装体稳定存在, 显示出很好的氧化响应特性. 细胞培养结果表明, 表面带正电荷的共负载微载体易被HepG2细胞内吞, 并可转染, 且随着DOX的释放逐渐杀死HepG2肝癌细胞, 为安全稳定、 具有刺激响应的药物与基因共负载微载体的制备提供了可行的途径.     

兼具MRI显影增强及pH敏感释药性能的载药Fe_3O_4纳米颗粒

以聚丙烯酸(PAA)修饰的超顺磁性Fe_3O_4纳米颗粒(MNPs-PAA)为基础,利用pH敏感的腙键将抗肿瘤药物阿霉素(DOX)与磁性颗粒表面的PAA链偶联,制备了载药Fe_3O_4磁性纳米颗粒(MNPs-DOX)。通过透射电镜、X射线衍射、紫外、红外、热失重以及体外磁共振显影(MRI)等手段对MNPs-DOX的形貌、结构、MRI及载释药效果进行了表征。结果证实,MNPsDOX具有超顺磁性,在MRI中具备良好的横向弛豫(T2)显影增强效果。此外,其DOX负载率达15%(质量分数),且在pH=5.0的酸性环境中药物释放量明显高于pH=7.4的中性环境,具有对环境pH的敏感性。     

5-氟尿嘧啶在pH敏感型分子筛控释载体中的缓释行为

以肠溶性的羟丙基甲基纤维素邻苯二甲酸酯(HPMCP)作为包覆材料,制备了HPMCP包覆的SBA-15介孔分子筛药物控释载体(HPMCP/SBA-15),并考察了抗癌药物5-氟尿嘧啶(5-Fu)负载于控释载体后,在不同pH释放环境中的释放行为.结果表明,在模拟胃液中(pH=1.2),HPMCP能明显地延缓5-Fu的释放速度;药物释放4h后,其释放率仅为15%.而在模拟肠液中(pH=7.5)HPMCP迅速溶解,对5-Fu释放速度的影响甚微;药物释放4h后,释放率可达到80%.与此同时,包覆膜的干燥温度影响5-Fu的释放行为,干燥温度越高,药物在模拟胃液中的释放速度越慢.     

pH响应性聚合物胶束的制备、表征及对阿霉素的控制释放研究

以主链含腙键的聚乙二醇大分子(PEG-NH-N=CH-OH)为引发剂,通过开环聚合己内酯(ε-CL),制备了一种具有pH响应性的两亲性嵌段共聚物PEG-NH-N=CH-PCL.运用核磁共振(~1H NMR)、透射电镜(TEM)和动态光散射(DLS)等对聚合物的结构、胶束的形貌及粒径进行表征.结果表明,聚合物胶束呈规整球形且分布均匀,平均粒径约98nm,pH 5.0时胶束粒径显著增加.负载阿霉素(DOX)的聚合物胶束的载药量为16.4%,包封率为57.4%.体外释放研究表明,pH 5.0时药物释放速率比pH 7.4时快,48h后累计释放率达91.1%.因此,该pH响应性聚合物胶束作为抗癌药物载体具有潜在的应用价值.     

中空介孔硅球原位接枝聚苯胺及其pH响应性药物控制释放行为

通过原位化学氧化聚合的方法,在中空介孔二氧化硅纳米粒子表面成功接枝上了聚苯胺(HMSsPANI).借助透射电镜(TEM)、红外光谱(FTIR)、紫外可见吸收光谱(UV-Vis)、氮气脱附吸附等温测试(BET)、热失重(TGA)、小角粉末衍射(XRD)和zeta电位测试等手段表征了其结构性质.通过循环伏安曲线研究,发现HMSs-PANI分散体系在不同pH条件下具有电化学活性的转变性质,证实了HMSs-PANI在酸性条件下能够进行有效的掺杂从而具有电化学活性.最后用HMSs-PANI来负载抗癌药物盐酸阿霉素(DOX),其展现了良好的酸性pH可控释放行为,在pH=7.4时,22 h后仅有15%的药物累计释放量.在pH=5的条件下,22 h后累计释放量达到44%,而在pH=4条件且同样时间之下,释放量为60%.总之,合成的HMSs-PANI酸响应药物控制释放体系在药物传输领域具有潜在应用.     

新型结合阿霉素的聚乙二醇嵌段共聚树枝状聚赖氨酸的合成及其药物缓释行为的研究

采用液相多肽合成方法, 成功制备得到窄分子量分布、结构确定的聚乙二醇嵌段共聚四代树枝状聚赖氨酸 (MPEG-block-DPL4). 在此基础上, 进一步将其DPL4的端氨基转化为端肼基, 并通过其与抗肿瘤药物阿霉素(DOX) C＝O的反应形成C＝N键, 实现在DPL4表面的阿霉素药物分子化学结合, 最终得到新型pH敏感性的高分子药物MPEG-block-DPL4-CONHN＝DOX. 运用紫外分光光度(UV-Vis)法, 对MPEG-block-DPL4-CONHNH₂与阿霉素的负载效率进行了定量分析. 高分子药物MPEG-block-DPL4-CONHN＝DOX在生理条件(pH＝7.4)下相对稳定, 而弱酸性条件(pH＝4.5, 5.5)下, C＝N键能较快水解, 释放阿霉素药物分子. 体外细胞毒性评价结果表明(细胞株SMMC-7721和SPCA-1), 所得新型高分子药物MPEG-block-DPL4-CONHN＝DOX的细胞毒性显著地低于游离阿霉素药物分子, 因此, 可进一步研究发展成为新型pH敏感性可控缓释高分子抗肿瘤药物载体体系.     

基于壳聚糖的pH响应双重药物释放系统研究

以腙键连接的壳聚糖阿霉素前药偶联物(Chitosan-hz-DOX)为载体,通过物理包埋法制备了负载喜树碱(CPT)的双药共传递纳米输送体系(CPT-CS-DOX).通过紫外可见吸收光谱、动态光散射、透射扫描电镜等方法研究了体系的粒径、形貌、药物负载及释放性能,发现制备CPT-CS-DOX纳米颗粒的最佳CPT投放量为20%,其粒径随着Chitosan-hz-DOX中阿霉素(DOX)含量的增加而不断降低,共传递体系有效地抑制了DOX和CPT的早期泄露,并呈现出显著的p H依赖药物释放行为.利用Peppas方程对释放曲线进行分析,发现第一阶段DOX和CPT在中性环境中的释放遵循Fick扩散控制和溶胀控制机理,在酸性环境中CPT的释放机理保持不变,而DOX的释放则转变为聚合物松弛机理;第二阶段则两者均符合Fick扩散机理.     

pH/酶/光热多重响应的金纳米笼/透明质酸核壳结构纳米载体的制备与性能

以金纳米笼(AuNC)为核, 巯基化改性的透明质酸(LC-HA)为壳, 盐酸阿霉素(DOX)为药物模型, 通过简单的一锅法制备了核壳结构载药纳米粒子DOX@AuNC@HA(DAH). 金纳米笼为药物装载提供容器且赋予载体光热性能, 改性的透明质酸对金纳米笼进行包封并提供pH/酶响应及靶向介导功能. 对DAH的结构进行了表征, 并进行了载药、 控释性能以及细胞摄取和细胞毒性的研究. 结果表明, 核壳结构纳米微粒DAH具有较高的载药能力, 在激光源的照射下具有较好的循环稳定性和较高的光热转换率. 在pH=7.4的磷酸盐缓冲液中, DAH具有较高的稳定性, 20 h的药物泄露率低于20%; 而在酸性环境、 透明质酸酶(HAase)及光热作用下, DAH均能较快地释放出装载的药物, 展现出较好的刺激响应性. 此外, DAH能够更多地被肿瘤细胞摄取, 表现出一定的靶向性; 当化疗与光热疗法共同作用时, 肿瘤细胞的活性大大减弱, 展现出了联合疗法的优势及潜力.     

抗癌载药体系Fe_3O_4@ZIF-8@PA的合成及药物释放

采用溶剂热法合成磁性Fe_3O_4纳米粒子,并以此为基底设计制备了一种具有pH响应核壳结构的磁性纳米复合材料Fe_3O_4@ZIF-8@PA.该材料的比饱和磁化强度可达35.46 A·m2/g,具有良好的磁性.Fe_3O_4纳米粒子呈球型结构,分散性良好.与基底相比,复合微球的粒径尺寸明显增大,但依然符合载体材料的理想尺寸且分布均匀.此外,载体具有多孔结构,表面积较大,载药效率和载药量分别高达96.4%和144.6 mg/g.在pH为7.4和5.0的条件下对载药纳米粒子进行了药物释放研究.24 h内,粒子在2种pH下累计释放量分别为39.8%和78.6%.通过药物缓释验证了载体的pH响应性能.在实验中引入了对癌细胞具有杀伤作用的植酸,使合成的载体具有一定的抗癌作用.同时采用四甲基偶氮唑盐(MTT)法对人骨肉瘤细胞(MG-63)进行了体外分析实验,证实材料与抗癌药物阿霉素(DOX)之间存在着一定的协同抗癌效果.     

Synthesis of self-assemble pH-responsive cyclodextrin block copolymer for sustained anticancer drug delivery

Well-defined p H-responsive poly(ε-caprolactone)-graft-β-cyclodextrin-graft-poly(2-(dimethylamino)ethylmethacrylate)-co-poly(ethylene glycol) methacrylate amphiphilic copolymers(PCL-g-β-CD-g-P(DMAEMA-co-PEGMA)) were synthesized using a combination of atom transfer radical polymerization(ATRP),ring opening polymerization(ROP) and "click" chemistry.Successful synthesis of polymers was confirmed by Fourier transform infrared spectroscopy(FTIR),proton nuclear magnetic resonance(1H-NMR),and gel permeation chromatography(GPC).Then,the polymers could selfassemble into micelles in aqueous solution,which was demonstrated by dynamic light scattering(DLS) and transmission electron microscopy(TEM).The p H-responsive self-assembly behavior of these copolymers in water was investigated at different p H values of 7.4 and 5.0 for controlled doxorubicin(DOX) release,and these results revealed that the release rate of DOX could be effectively controlled by altering the p H,and the release of drug loading efficiency(DLE) was up to 88%(W/W).CCK-8 assays showed that the copolymers had low toxicity and possessed good biodegradability and biocompatibility,whereas the DOX-loaded micelles remained with high cytotoxicity for He La cells.Moreover,confocal laser scanning microscopy(CLSM) images revealed that polymeric micelles could actively target the tumor site and the efficient intracellular DOX release from polymeric micelles toward the tumor cells further confirmed the anti-tumor effect.The DOX-loaded micelles could easily enter the cells and produce the desired pharmacological action and minimize the side effect of free DOX.These results successfully indicated that p H-responsive polymeric micelles could be potential hydrophobic drug delivery carriers for cancer targeting therapy with sustained release.     

线性麦芽糊精聚合物功能化Fe3O4纳米复合物药物载体的合成和应用

采用共沉淀法制备得到了线性麦芽糊精聚合物功能化的Fe₃O₄磁性纳米粒子(LM-SP-MNPs),通过傅里叶变换红外光谱、透射电子显微镜、热重分析等技术对其结构、形貌进行了表征。 其粒径大小为(12±2) nm。 选取抗癌药物盐酸阿霉素(DOX)作为模型药物,运用荧光光谱法研究了LM-SP-MNPs的载药性能和释放行为,探讨了pH值对LM-SP-MNPs药物释放性能的影响。 最适pH条件下,LM-SP-MNPs对盐酸阿霉素的最大吸附量约为357.1 mg/g,吸附等温线符合Freundlich等温吸附模型。 LM-SP-MNPs与盐酸阿霉素的复合物(DOX@LM-SP-MNPs),在37 ℃的条件下药物在酸性条件下的释放效率大于中性条件。 pH=5.3时,盐酸阿霉素在7 h内的累积释放率为26.9%。 此外,细胞毒性试验表明,LM-SP-MNPs具有良好的生物相容性,而DOX@LM-SP-MNPs和肝癌细胞共培养后可以明显杀死HepG2肝癌细胞。     

pH‐sensitive carbon quantum dots−doxorubicin nanoparticles for tumor cellular targeted drug delivery

A kind of pH‐responsive carbon quantum dots?doxorubicin nanoparticles drug delivery platform (D‐Biotin/DOX‐loaded mPEG‐OAL/N‐CQDs) was designed and synthesized. The system consists of fluorescent carbon dots as cross‐linkers, and D‐Biotin worked as targeting groups, which made the system have a pH correspondence, doxorubicin hydrochloride (DOX) as the target drug, oxidized sodium alginate (OAL) as carrier materials. Ultraviolet (UV)‐Vis spectrum showed that the drug‐loading rate of DOX is 10.5%, and the drug release in vitro suggested that the system had a pH response and tumor cellular targeted, the drug release rate is 65.6% at the value of pH is 5.0, which is much higher than that at the value of pH is 7.4. The cytotoxicity test and laser confocal fluorescence imaging showed that the synthesized drug delivery system has high cytotoxicity to cancer cells, and the drug‐loaded nanoparticles could enter the cells through endocytosis.     

Liposomes‐Camouflaged Redox‐Responsive Nanogels to Resolve the Dilemma between Extracellular Stability and Intracellular Drug Release

Liposomes have shown great promises for pharmaceutical applications, but still suffer from the poor storage stability, undesirable drug leakage, and uncontrolled drug release. Herein, liposomes‐camouflaged redox‐responsive nanogels platform (denoted as “R‐lipogels”) is prepared to integrate the desirable features of sensitive nanogels into liposomes to circumvent their intrinsic issues. The results indicate that drug‐loaded R‐lipogels with controlled size and high stability not only can achieve a very high doxorubicin (DOX)‐loading capacity (12.9%) and encapsulation efficiency (97.3%) by ammonium sulfate gradient method and very low premature leakage at physiological condition, but also can quickly release DOX in the reducing microenvironment of tumor cells, resulting in effective growth inhibition of tumor cells. In summary, the strategy given here provides a facile approach to develop liposomes–nanogels hybrid system with combined beneficial features of stealthy liposomes and responsive nanogels, which potentially resolves the dilemma between systemic stability and intracellular rapid drug release.     

Synthesis of poly(acrylic acid) (PAA) modified Pluronic P123 copolymers for pH-stimulated release of doxorubicin

Pluronic P123 was chain-extended at their terminal groups using atom transfer radical polymerization to form poly(acrylic acid) (PAA) tails and obtain the PAA-b-P123-b-PAA (P123-PAA) copolymer. The incorporation of PAA had the effect of increasing the carrier's drug loading capacity of an anti-cancer drug, Doxorubicin (DOX), and also allowed for pH-controlled release of the drug. Drug release assays showed that up to 60% of DOX cargo could be retained in the DOX/P123-PAA complex for 3 days at normal physiological pH (7.4). This was then followed by a secondary burst release of DOX when the environment became more acidic (pH 5). Therefore, it was possible that the more acidic physiological environment of tumor sites could be used to trigger an accelerated release of DOX from the drug carriers. The material was demonstrated for potential application in the delivery of cationic drugs for cancer treatment.     

Co‐delivery of 10‐Hydroxycamptothecin with Doxorubicin Conjugated Prodrugs for Enhanced Anticancer Efficacy

Well‐defined amphiphilic linear‐dendritic prodrugs (MPEG‐b‐PAMAM‐DOX) are synthesized by conjugating doxorubicin (DOX), to MPEG‐b‐PAMAM through the acid‐labile hydrazone bond. The amphiphilic prodrugs form self‐assembled nanoparticles in deionized water and encapsulate the hydrophobic anticancer drug 10‐hydroxycamptothecin (HCPT) with a high drug loading efficiency. Studies on drug release and cellular uptake of the co‐delivery system reveal that both drugs are released in a pH‐dependent manner and effectively taken up by MCF‐7 cells. In vitro methyl thiazolyl tetrazolium (MTT) assays and drug‐induced apoptosis tests demonstrate the HCPT‐loaded nanoparticles suppress cancer cell growth more efficiently than the MPEG‐b‐PAMAM‐DOX prodrugs, free HCPT, and physical mixtures of MPEG‐b‐PAMAM‐DOX and HCPT at equivalent DOX or HCPT doses.

     

Preparation of polyprenol/poly (β-amino ester)/galactose targeted micelle carrier for enhancing cancer therapy

Lacking of substantial physiological activity and low utilization remains a problem for most conventional drug carriers. Polyprenol with beneficial medical effects and high availability could be an ideal candidate for solving this issue. Here, Ginkgo biloba leaves polyprenol (GBP)-based derivative was prepared by Michael addition reaction of poly (β-amino esters) (PBAE) with GBP and galactose (Gal). The intervention of poly (β-amino ester) and galactose promoted GBP-PBAE-Gal to depict as micellar carrier, enhancing the loading of hydrophobic DOX and the sensitivity to the specific tumor microenvironment, with the largest DOX loading of 28.62 ± 1.49 % and the efficient DOX release rate of 90.30 %. In the meantime, GBP-PBAE-Gal exhibited enhanced colloidal stability at 640-folds of dilution and in the presence of serum and realized the possibility of long-term storage at room temperature. Additionally, GBP-PBAE-Gal was safe for human red blood cells and human normal liver cells HL-7702. When applied for DOX delivery to HepG2 cells, GBP-PBAE-Gal increased the targeting of DOX to intensify its inhibition on HepG2 cells. Compared to free DOX, the DOX loaded into GBP-PBAE-Gal presented stronger anticancer activity, with IC₅₀ of 0.56 μg/mL at 72 h. Besides, the anticancer mechanism study revealed that GBP-PBAE-Gal arrested the cell cycle in HepG2 cells, suggesting the potential of GBP-based carrier for intensive treatment. This research evidenced the feasibility and high availability of the GBP to use as a drug carrier, providing a novel candidate for drug delivery systems.     

Metal–organic frameworks as efficient materials for drug delivery: Synthesis,characterization, antioxidant,anticancer, antibacterial and molecular docking investigation

Metal–organic framework (MOF) nano particles are a class of promising porous nano materials for biomedical applications. Owing to its high loading potential and pH-sensitive degradation, most promising of the MOFs is the zeolitic imidazolate crystal framework (ZIF-8), a progressive useful material for small molecule distribution. Doxorubicin (DOX), designated as a classical drug, was jobwise entrapped in ZIF-8 nano particles. ZIF-8 nano particles, as a novel carrier, were used to monitor the release of the anticancer drug DOX and prevent it from dissipating before reaching its goal. ZIF-8 nano particles with encapsulated DOX (DOX@ZIF-8) can be synthesized in a single pot by incorporation of DOX into the reaction mixture. MOFs and the designed drug delivery (DOX@ZIF-8) system were characterized by Fourier transfer infrared, scanning electron microscopy, N₂ sorption isotherm and X-ray diffraction. The impact of MOFs and the engineered drug delivery system on the viability of human breast and liver cancer cell lines was evaluated. The loaded drug was released at pH 5 faster than at pH 7.4. The nano particles of ZIF-8 showed low cytotoxicity, while DOX@ZIF-8 showed high cytotoxicity to HepG-2 and MCF-7 cells compared with free DOX at the equivalent concentration of DOX of >12.5 μg/ml. These findings indicate that DOX@ZIF-8 nano particles are a promising method for the delivery of cancer cells to drugs. Furthermore, ZIF-8, DOX and encapsulated DOX@ZIF-8 compounds were screened for their potential antibacterial activities against pathogenic bacteria compared with standard antibiotics by the agar well diffusion technique. The results demonstrate that the DOX@ZIF-8 exhibits a strong inhibition zone against Gram-negative strains (Escherichia coli) in comparison with the reference drug gentamycin. The docking active site interactions were evaluated to predict the binding between DOX with the receptor of breast cancer 3hb5-oxidoreductase and liver cancer 2h80-lipid binding protein for anticancer activity.